Payment overview · 2025
General Payments
$15,935.90
371 reported records · 36 companies
Healthcare provider profile · identity verified
Neil Gilbert, M.D.
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · LATHRUP VILLAGE, MI · NPI 1053371658
Verified facts
What the public records show
CMS Open Payments records show Neil Gilbert, M.D. received $15,935.90 in general payments during 2025 across 371 reported records.
Lilly USA, LLC accounted for 61.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 50 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Austedo Xr, Vumerity.
ACADIA Pharmaceuticals Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUPLAZID as an associated drug or biological on 20845 records involving 6448 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Nuplazid by this doctor in 2024.
Amneal Pharmaceuticals LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RYTARY as an associated drug or biological on 200 records involving 121 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Rytary by this doctor in 2024.
Biogen, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VUMERITY as an associated drug or biological on 16193 records involving 4044 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Vumerity by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO as an associated drug or biological on 28 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Austedo by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO XR as an associated drug or biological on 86263 records involving 23643 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Austedo Xr by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $9,735.30 | 61.1% | 19 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $888.14 | 5.6% | 48 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $489.32 | 3.1% | 32 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $384.33 | 2.4% | 29 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $379.67 | 2.4% | 20 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $313.47 | 2.0% | 21 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $277.83 | 1.7% | 18 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$257.84 | 1.6% | 13 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $249.52 | 1.6% | 15 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $238.23 | 1.5% | 15 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $223.30 | 1.4% | 9 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $221.60 | 1.4% | 13 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $210.88 | 1.3% | 14 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $193.49 | 1.2% | 17 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $192.15 | 1.2% | 3 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $187.07 | 1.2% | 10 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $186.62 | 1.2% | 7 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $186.57 | 1.2% | 8 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $139.61 | 0.9% | 7 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $138.27 | 0.9% | 11 | 2025 |
| Tanabe Pharma America, Inc. | Unresolved — no canonical attribution shown | $118.63 | 0.7% | 5 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $104.45 | 0.7% | 4 | 2025 |
| Aucta Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $94.10 | 0.6% | 9 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $73.73 | 0.5% | 3 | 2025 |
| Cycle Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $70.15 | 0.4% | 4 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $66.39 | 0.4% | 3 | 2025 |
| LivaNova USA, Inc. | Unresolved — no canonical attribution shown | $62.16 | 0.4% | 2 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $47.98 | 0.3% | 2 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$43.13 | 0.3% | 2 | 2025 |
| CATALYST PHARMACEUTICALS, INC. | Unresolved — no canonical attribution shown | $36.24 | 0.2% | 2 | 2025 |
| Otter Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $27.41 | 0.2% | 1 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $23.40 | 0.1% | 1 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.02 | 0.1% | 1 | 2025 |
| TG Therapeutics, Inc. | Unresolved — no canonical attribution shown | $18.90 | 0.1% | 1 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $17.46 | 0.1% | 1 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.54 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $8,200.00 | 2 |
| Food and Beverage | $6,523.86 | 365 |
| Travel and Lodging | $1,151.04 | 3 |
| Education | $61.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $8,542.32 | 13 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $489.32 | 32 | 2025 |
Source payment records
|
|||||
| Fintepla Normalized: fintepla |
Drug | UCB, Inc. | $436.70 | 19 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $318.47 | 14 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $313.47 | 21 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $283.71 | 19 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $282.42 | 19 | 2025 |
Source payment records
|
|||||
| PONVORY Normalized: ponvory |
Drug | Vanda Pharmaceuticals Inc. | $277.83 | 18 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $257.84 | 13 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $256.78 | 21 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $223.30 | 9 | 2025 |
Source payment records
|
|||||
| CREXONT Normalized: crexont |
Drug | Amneal Pharmaceuticals LLC | $221.60 | 13 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $193.49 | 17 | 2025 |
Source payment records
|
|||||
| Gamunex-C Normalized: gamunex c |
Biological | Grifols USA, LLC | $192.15 | 3 | 2025 |
Source payment records
|
|||||
| TYSABRI Normalized: tysabri |
Biological | Biogen, Inc. | $188.42 | 13 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $188.41 | 14 | 2025 |
Source payment records
|
|||||
| HYQVIA Normalized: hyqvia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $187.07 | 10 | 2025 |
Source payment records
|
|||||
| WAINUA Normalized: wainua |
Drug | AstraZeneca Pharmaceuticals LP | $186.62 | 7 | 2025 |
Source payment records
|
|||||
| XYWAV Normalized: xywav |
Drug | JAZZ PHARMACEUTICALS INC. | $177.55 | 9 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $150.43 | 10 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $139.61 | 7 | 2025 |
Source payment records
|
|||||
| ZEPOSIA Normalized: zeposia |
Drug | Celgene Corporation | $138.27 | 11 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $130.90 | 4 | 2025 |
Source payment records
|
|||||
| UZEDY Normalized: uzedy |
Drug | Teva Pharmaceuticals USA, Inc. | $121.35 | 1 | 2025 |
Source payment records
|
|||||
| Radicava Normalized: radicava |
Drug | Tanabe Pharma America, Inc. | $118.63 | 5 | 2025 |
Source payment records
|
|||||
| Nayzilam Normalized: nayzilam |
Drug | UCB, Inc. | $108.57 | 12 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $104.45 | 4 | 2025 |
Source payment records
|
|||||
| Motpoly XR Normalized: motpoly xr |
Drug | Aucta Pharmaceuticals, Inc. | $94.10 | 9 | 2025 |
Source payment records
|
|||||
| DAYBUE Normalized: daybue |
Drug | ACADIA Pharmaceuticals Inc | $73.73 | 3 | 2025 |
Source payment records
|
|||||
| EPIDIOLEX Normalized: epidiolex |
Drug | JAZZ PHARMACEUTICALS INC. | $71.97 | 6 | 2025 |
Source payment records
|
|||||
| Tascenso ODT Normalized: tascenso odt |
Drug | Cycle Pharmaceuticals Inc | $70.15 | 4 | 2025 |
Source payment records
|
|||||
| AJOVY Normalized: ajovy |
Biological | Teva Pharmaceuticals USA, Inc. | $69.91 | 5 | 2025 |
Source payment records
|
|||||
| ONPATTRO Normalized: onpattro |
Drug | Alnylam Pharmaceuticals Inc. | $66.39 | 3 | 2025 |
Source payment records
|
|||||
| VNS THERAPY SENTIVA MODEL 1000 GENERATOR Normalized: vns therapy sentiva model 1000 generator |
Device | LivaNova USA, Inc. | $62.16 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $55.67 | 4 | 2025 |
Source payment records
|
|||||
| Bafiertam Normalized: bafiertam |
Drug | Cycle Pharmaceuticals Inc | $52.61 | 3 | 2025 |
Source payment records
|
|||||
| FYCOMPA Normalized: fycompa |
Drug | CATALYST PHARMACEUTICALS, INC. | $36.24 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $34.26 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $33.34 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $33.34 | 2 | 2025 |
Source payment records
|
|||||
| SYMPAZAN Normalized: sympazan |
Drug | Otter Pharmaceuticals, LLC | $27.41 | 1 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $22.81 | 3 | 2025 |
Source payment records
|
|||||
| SKYCLARYS Normalized: skyclarys |
Drug | Biogen, Inc. | $22.46 | 1 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $22.02 | 1 | 2025 |
Source payment records
|
|||||
| BRIUMVI Normalized: briumvi |
Drug | TG Therapeutics, Inc. | $18.90 | 1 | 2025 |
Source payment records
|
|||||
| Briviact Normalized: briviact |
Drug | UCB, Inc. | $18.02 | 2 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $17.46 | 1 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $14.95 | 1 | 2025 |
Source payment records
|
|||||
| AVONEX Normalized: avonex |
Biological | Biogen, Inc. | $11.56 | 1 | 2025 |
Source payment records
|
|||||
| Vimpat Normalized: vimpat |
Drug | UCB, Inc. | $6.38 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AUSTEDO XR austedo xr |
2025 | Austedo Xr | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VUMERITY vumerity |
2025 | Vumerity | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ACADIA Pharmaceuticals Inc Exact reporting entity; no affiliate inference |
2025 | NUPLAZID open payments reported associated product |
CMS Open Payments — General Payments 20845 supporting records · 6448 recipient NPIs · example record 1247763852 |
Nuplazid · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Amneal Pharmaceuticals LLC Exact reporting entity; no affiliate inference |
2025 | RYTARY open payments reported associated product |
CMS Open Payments — General Payments 200 supporting records · 121 recipient NPIs · example record 1220526035 |
Rytary · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Biogen, Inc. Exact reporting entity; no affiliate inference |
2025 | VUMERITY open payments reported associated product |
CMS Open Payments — General Payments 16193 supporting records · 4044 recipient NPIs · example record 1208299697 |
Vumerity · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 15 recipient NPIs · example record 1247249192 |
Austedo · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO XR open payments reported associated product |
CMS Open Payments — General Payments 86263 supporting records · 23643 recipient NPIs · example record 1247244228 |
Austedo Xr · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Pregabalin | Pregabalin | 640 | 193 |
| Gabapentin | Gabapentin | 302 | 80 |
| Amitriptyline Hcl | Amitriptyline Hcl | 283 | 106 |
| Topiramate | Topiramate | 275 | 67 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 254 | 51 |
| Donepezil Hcl | Donepezil Hcl | 209 | 65 |
| Levetiracetam | Levetiracetam | 198 | 38 |
| Trazodone Hcl | Trazodone Hcl | 190 | 58 |
| Buspirone Hcl | Buspirone Hcl | 189 | 55 |
| Celecoxib | Celecoxib | 174 | 84 |
| Alprazolam | Alprazolam | 160 | 44 |
| Primidone | Primidone | 151 | 34 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 111 | 36 |
| Methocarbamol | Methocarbamol | 109 | 52 |
| Lacosamide | Lacosamide | 104 | 18 |
| Sertraline Hcl | Sertraline Hcl | 102 | 19 |
| Olanzapine | Olanzapine | 100 | 24 |
| Memantine Hcl | Memantine Hcl | 93 | 22 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 91 | 20 |
| Lamotrigine | Lamotrigine | 90 | 12 |
| Atorvastatin Calcium | Atorvastatin Calcium | 80 | 26 |
| Divalproex Sodium Er | Divalproex Sodium | 76 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 76 | 23 |
| Diclofenac Sodium | Diclofenac Sodium | 74 | 43 |
| Escitalopram Oxalate | Escitalopram Oxalate | 70 | 22 |
| Clopidogrel | Clopidogrel Bisulfate | 69 | 30 |
| Midodrine Hcl | Midodrine Hcl | 69 | 15 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 69 | 32 |
| Quetiapine Fumarate | Quetiapine Fumarate | 67 | 15 |
| Baclofen | Baclofen | 65 | 17 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 65 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 61 | 11 |
| Methylprednisolone | Methylprednisolone | 57 | 51 |
| Tizanidine Hcl | Tizanidine Hcl | 57 | 18 |
| Oxybutynin Chloride | Oxybutynin Chloride | 56 | 15 |
| Oxcarbazepine | Oxcarbazepine | 54 | suppressed |
| Clonazepam | Clonazepam | 53 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 51 | suppressed |
| Carbamazepine Er | Carbamazepine | 49 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 48 | 17 |
| Mirtazapine | Mirtazapine | 43 | 16 |
| Propranolol Hcl Er | Propranolol Hcl | 43 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 42 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 39 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 37 | 11 |
| Rivastigmine | Rivastigmine Tartrate | 35 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 34 | 12 |
| Carisoprodol | Carisoprodol | 34 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 34 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 33 | 11 |
| Tramadol Hcl | Tramadol Hcl | 33 | 24 |
| Entacapone | Entacapone | 32 | suppressed |
| Ezetimibe | Ezetimibe | 32 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 32 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 29 | 11 |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 29 | suppressed |
| Amantadine | Amantadine Hcl | 28 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 28 | 13 |
| Prednisone | Prednisone | 28 | suppressed |
| Lidocaine | Lidocaine | 26 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 26 | suppressed |
| Lorazepam | Lorazepam | 25 | suppressed |
| Austedo | Deutetrabenazine | 23 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 23 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 22 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 21 | suppressed |
| Meloxicam | Meloxicam | 20 | suppressed |
| Phenytoin | Phenytoin | 20 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 18 | suppressed |
| Kesimpta Pen | Ofatumumab | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | suppressed |
| Carbamazepine | Carbamazepine | 17 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Rytary | Carbidopa/Levodopa | 16 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 15 | suppressed |
| Hydrocortisone | Hydrocortisone | 15 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 15 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 15 | suppressed |
| Vumerity | Diroximel Fumarate | 15 | suppressed |
| Austedo Xr | Deutetrabenazine | 14 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 14 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 14 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 14 | suppressed |
| Simvastatin | Simvastatin | 14 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Acetazolamide Er | Acetazolamide | 13 | suppressed |
| Furosemide | Furosemide | 13 | suppressed |
| Losartan Potassium | Losartan Potassium | 13 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 12 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 12 | suppressed |
| Omeprazole | Omeprazole | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 12 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 11 | suppressed |
| Scopolamine | Scopolamine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $15,935.90 · 371 records | Lilly USA, LLC | ACTHAR, AJOVY, AUSTEDO XR, AVONEX, BOTOX, BRIUMVI, Bafiertam, Briviact, CREXONT, DAYBUE, EPIDIOLEX, FYCOMPA, Fintepla, Gamunex-C, HYQVIA, INGREZZA, KESIMPTA, KISUNLA, Leqembi, MOUNJARO, Motpoly XR, NURTEC ODT, Nayzilam, ONPATTRO, PONVORY, QULIPTA, REXULTI, Radicava, Rystiggo, SKYCLARYS, SYMPAZAN, Symbravo, TYSABRI, Tascenso ODT, UBRELVY, ULTOMIRIS, UZEDY, VALTOCO, VNS THERAPY SENTIVA MODEL 1000 GENERATOR, VRAYLAR, VUMERITY, VYALEV, VYEPTI, VYVGART HYTRULO, Vimpat, WAINUA, XYWAV, ZAVZPRET, ZEPBOUND, ZEPOSIA | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Austedo Xr play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ACADIA Pharmaceuticals Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error